Download Poster (4.2 MB)
- The primary outcome was to measure the proportion of patients experiencing DIs before and after the ART switch.
- The secondary outcome was to measure changes in DI scores before and after the ART switch.
HIV, antiretroviral, drug interactions, bictegravir
Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences
Walshe, PharmD Candidate, Ciara and Schafer, PharmD, MPH, BCPS-AQ ID, BCIDP, AAHIVP, Jason J., "The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir alafenamide in Treatment Experienced Patients" (2020). College of Pharmacy Posters. 21.